A Study to Evaluate the Efficacy and Safety of LNK01004 Ointment in Adults With Atopic Dermatitis

This study will evaluate the efficacy and safety of two concentrations (0.3 percent \[%\] and 1%) of twice daily LNK01004 ointment for the topical treatment in adult subjects with atopic dermatitis. This is a multicenter, randomized, double-blind, vehicle-controlled, 3-arm, parallel-group, dose-finding study in adult subjects with atopic dermatitis. Two concentrations of LNK01004 ointment (0.3% and 1%) and a vehicle control ointment will be equally randomized and evaluated following application to all atopic dermatitis lesions (except on the scalp) twice daily (morning and evening) for 8 weeks. This study will consist of 3 periods: up to 4 weeks screening, 8 weeks double-blind treatment, and 2 weeks post-treatment follow-up. Approximately 75 subjects (25 subjects for each group) with moderate to severe AD will be enrolled overall.

NCT Number	NCT07071610
Lead Sponsor	Lynk Pharmaceuticals Co., Ltd
Conditions	Atopic Dermatitis
Enrollment	75 participants
Start Date	2025-03-18
Primary Completion	2025-07-24 (estimated)
Study Completion	2025-07-24 (estimated)
Updated on ClinicalTrials.gov	2026-01-14